Alumis Inc. (ALMS) stock
ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.39−0.45 (-9.19%)
Close on Nov 18, 2026Market cap $568.87MP/E –Yield –
Alumis operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Alumis's operating income for the twelve months ending Jun 30, 2026 was -$459.00M. For fiscal 2025 it was -$453.80M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$453.80M | – |
| FY2024 | Dec 31, 2024 | -$300.75M | – |
| FY2023 | Dec 31, 2023 | -$158.17M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$148.86M | – |
| Q1 FY2026 | Mar 31, 2026 | -$98.41M | – |
| Q4 FY2025 | Dec 31, 2025 | -$96.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$115.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$140.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$101.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$98.62M | – |
| Q3 FY2024 | Sep 30, 2024 | -$98.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$56.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$47.59M | – |
| Q4 FY2023 | Dec 31, 2023 | -$40.13M | – |
| Q3 FY2023 | Sep 30, 2023 | -$43.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.62M | – |
See a number that looks wrong?